Me-too, In-Fashion Investing Fueling A Social Media Bubble

John Steuart

I was struck recently by a piece in The Wall Street Journal by Pui-Wing Tam, The $1 Billion Club Gets Crowded, which highlights the amusing rate at which closely held, private US companies in the social media sector are garnering $1 billion-plus valuations. With 20 companies already fetching a 10-figure price tag— 15 of them since the beginning of last year— the bubble has swelled quickly. Even during the dot-com boom of . . .
→ Read full post: Me-too, In-Fashion Investing Fueling A Social Media Bubble

IPOs look dicey, but private equity may pick up some of the slack

Randy Hawks

September 15, 2011 source: Xconomy

For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. In the first half of 2011, there were 36 IPOs, right on target for at least a replay . . .
→ Read full post: IPOs look dicey, but private equity may pick up some of the slack

Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation

John Steuart

I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center.

Here’s the panel topic summary, hope to see you there.

Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult . . .
→ Read full post: Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation

What Does It Take to Swing the IPO Window Open for Biotechs? – Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.

June 22, 2011 source: Genetic Engineering and Biotechnology News

On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the public offering,” Ambit CFO Alan Fuhrman said in an SEC filing.

The company’s about-face caps about a year . . .
→ Read full post: What Does It Take to Swing the IPO Window Open for Biotechs? – Suggestions include selling at a discount at a time when there is a rising investor fan-base for social media.

Trends Bode Well For Clean Tech IPOs This Year

March 2011 source: Financial Executives International (download a pdf reprint of the article)

Over the years, venture capitalists have invested in clean technology and renewable energy with the expectation that returns will take a long time. The VCs were right.

Development of technologies such as solar cell manufacturing, utility-scale renewable energy projects and genetically engineered algae for bio-fuels do indeed have great promise. But they require great patience.

Yet, with the . . .
→ Read full post: Trends Bode Well For Clean Tech IPOs This Year

The Argument for the Secondary Market

February 16, 2011 source: this guest blog post originally appeared on peHUB

There has been a lot of buzz around highflying companies allowing sales of their stock on secondary trading platforms. There have always been opportunities for individual secondary sales in private companies but nothing to match the current level of action. Before, occasional private party sales were allowed by company boards for purposes such as individuals buying a new house and funding . . .
→ Read full post: The Argument for the Secondary Market

Guest Post: 2011 Is the Year of the IPO

December 17, 2010 source: GreenTech Solar

Nat’s post “2011 Is the Year of the IPO” was featured on GreenTech Solar

Enphase, MiaSolé and BrightSource could all go public in a rebounding economy focused on green, contends Claremont Creek’s Nat Goldhaber.

Given the enormous brouhaha that has surrounded clean technology for several years, the wait for a flurry of clean tech IPOs may seem interminable. It may just about be over, however, because 2011 looks as . . .
→ Read full post: Guest Post: 2011 Is the Year of the IPO

What to watch for in cleantech in 2011: companies, IPOs and trends

December 10, 2010 source: VentureBeat

What to watch for in cleantech in 2011: companies, IPOs and trends

Tis the season for next-year forecasts, so VentureBeat asked a few cleantech venture capitalists for their thoughts on clean energy trends to watch in 2011.

Nat Goldhaber of Claremont Creek Ventures tells us that next year is The Year for some good old IPO action in green (we list a few of the . . .
→ Read full post: What to watch for in cleantech in 2011: companies, IPOs and trends

Cleantech Crystal Ball

I spoke to Venture Capital Journal’s reporter Mark Boslet about the Cleantech market recently. My thoughts appeared in the November issue of the publication. Here is an excerpt of what we discussed.

It has been a long time coming, but 2011 is looking like a pivotal year for cleantech IPOs. Suddenly the IPO market for cleantech companies looks more inviting. Electric carmaker Tesla Motors continues to trade above its June IPO price and biochemicals company Amyris . . .
→ Read full post: Cleantech Crystal Ball

Turbo Talks: Insights Into IPOs and Mergers & Acquisitions

Jamie Montgomery with Nat Goldhaber

On Wednesday September 15, my partners and I joined 22 of our portfolio companies and the Claremont Creek hosted speaker– investment bankers Jamie Montgomery, Eric Wagner, and Jason Yip– for our second Turbo Talks event this year. Turbo Talks refers to the gathering we created for our portfolio where we discuss timely topics of interest to many of them. During Turbo Talks, we get acquainted with each other and build . . .
→ Read full post: Turbo Talks: Insights Into IPOs and Mergers & Acquisitions